Crestor works by reducing a certain enzyme within the body that produces cholesterol. It belongs to a class of medications called statins.
Cholesterol is a form of lipid, a waxy substance that helps your body make cells, vitamins, and certain hormones. It is not inherently bad. Your liver produces an enzyme that synthesizes cholesterol to help with the above healthy functions. Additional cholesterol is introduced to the body through certain foods like meat, poultry, and dairy products.
There are two types of cholesterol: high-density lipoproteins (HDLs) and low-density lipoproteins (LDLs). LDLs carry cholesterol throughout the body, delivering cholesterol to cells that need it. HDLs carry excess LDLs back to the liver, where they are broken down and flushed from the body. While LDLs play a key role in cell health, they build up when the body has more cholesterol than the cells need. This buildup turns into plaque in the arteries (blood vessels). As plaque covers the artery walls, the blood vessels become narrow. This makes it harder for blood to flow through the body, which can lead to heart disease and heart failure.
Statins work by reducing the production of cholesterol in the liver, which lowers the overall cholesterol levels in the body. Not only do statins decrease levels of LDLs in the body, but they can also raise the level of HDLs in the body. In effect, they keep the body from making too much of the “bad” cholesterol that builds up in arteries while increasing the amount of “good” cholesterol that carries the “bad” out of the body. This dual action has been shown, along with diet and exercise, to lower overall cholesterol levels in patients effectively.
Crestor (Rosuvastatin) is a generic medication sold asustemir foetal (urgaft) tablets. Crestor (Rosuvastatin) is a generic medication sold asustemir foetal foetusAL (herbal preparation) which is a women’s cholesterol-lowering tablet that contains rosuvastatin. It is available in different strengths and is available in four dosage forms (250 mg, 500 mg, 1, 2 and 4 mg). In clinical studies, patients taking rosuvastatin were shown to have “slightly more stable cholesterol profiles” than patients taking a lower dosage of the medication. In one study, patients who took 500 mg of rosuvastatin and patients in clinical studies for at least 3 months to six months post-dose were shown to have “improved cholesterol profiles” than patients on the lower dosage. However, in another study, patients on the 1, 2 or 4 mg dosages lost almost 15% of their cholesterol levels while still having "improved profiles". This was due to rosuvastatin’s ability to lower "bad" cholesterol in the blood while still being taken in the appropriate dosage amount.�The clinical trials showed that patients on Crestor (Rosuvastatin) were slightly more likely to have "improved profiles" while taking the lower dosage of the medication. However, in one study, the clinical trials did not show a significant effect on "improved profiles". One limitation of rosuvastatin is that it may not be suitable for patients with certain medical conditions, such as high blood pressure, liver disease, or certain heart failure. Another limitation of Crestor is the potential side effects associated with the medication. Some patients have reported allergic reactions such as swelling of the lips, face, and throat, difficulty in breathing, and shortness of breath. Some of the side effects of rosuvastatin include nausea, vomiting, dizziness, itching, hay fever-like symptoms, abnormal liver tests, and allergic reactions like hives, itching, and difficulty in breathing.Please consult your doctor or pharmacist for more information.
Please contact us at your preferred site for further information or to schedule an consultation at any time of year. Warnings and CautionsActive ingredient:Rosuvastatin
Dosage:
The usual dosage amounts of Crestor (Rosuvastatin) in adults ranges from 1, 2, 4 mg orally once daily for a period of six months or more. Based on the effectiveness and toleration, a starting dose of 1, 2, 4 mg once daily is considered acceptable.
Background:Crestor is a statin commonly used to lower cholesterol levels. The FDA approved it for primary cholesterol management in 1997. However, recent meta-analyses have reported inconsistent results due to limited studies of statin use in people with elevated cholesterol levels. In this study, we present a prospective study that compared statin use in people with elevated cholesterol levels who had previously received statins or did not take statins. We report a single center, double-blind, randomized, placebo-controlled study that compared statin use in people with elevated cholesterol levels who had previously received statins to those in a comparable group who did not receive statins.
Methods:This study, enrolling a total of 755 adults ages 55 years and older with a serum lipid panel ≥5 mmol/L (the lowest risk of cardiovascular events, including stroke, heart failure, myocardial infarction, or cardiovascular death) was a secondary endpoint. Patients who were eligible for statin therapy (n = 237) were enrolled and randomized to receive either the statin or placebo arm (n = 237). They were assessed by a primary endpoint of the primary composite of the following measures: (1) change from baseline in lipid profile (including total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and apolipoprotein B, apolipoprotein A-I, and apolipoprotein A-II), (2) change from baseline in LDL cholesterol (LDL-C), and (3) change from baseline in HDL cholesterol (HDL-C).
Results:Among the 755 participants who received statin therapy, the primary endpoint was a composite of the primary composite measure of (3) change from baseline in LDL cholesterol (LDL-C), and (4) change from baseline in HDL cholesterol (HDL-C) (all analyses were performed in the primary endpoint) and (5) change from baseline in apolipoproteins (APOB), apolipoproteins-A-I (APOB-I), and apolipoprotein A-I-only (APOB-I-only) (all analyses were performed in the secondary endpoint). The results of the primary and secondary endpoint were statistically significant. When the primary endpoint was compared to the primary composite measure of LDL cholesterol (LDL-C), the difference between the statin and placebo groups was not significant; but there was a significant difference in the change from baseline in HDL cholesterol (HDL-C) between the statin group and the placebo group (all analyses were performed in the primary endpoint). The change from baseline in LDL cholesterol was statistically significant, but the difference between the statin group and the placebo group was not significant. In the secondary endpoint, there was a significant difference between the statin and placebo groups in the change from baseline in apolipoproteins (APOB-I) (all analyses were performed in the secondary endpoint), but there was no significant difference in the change from baseline in apolipoprotein A-I (APOB-I-only).
Conclusions:A recent meta-analysis that compared statin use in people with elevated cholesterol levels who had previously received statins with those in a comparable group who did not receive statins found that statin use was associated with elevated LDL-C levels.
A prospective study was performed to compare statin use in people with elevated cholesterol levels who had previously received statins and a comparable group who did not receive statins to those in a similar group who did not receive statins (n = 755) (Figure 1). The study was conducted at a total of 755 adults aged 55 years and older with a serum lipid panel ≥5 mmol/L (the lowest risk of cardiovascular events, including stroke, heart failure, myocardial infarction, or cardiovascular death) and a body mass index (BMI) ≥30 kg/m2. Patients with elevated cholesterol levels who were not otherwise instructed to receive statins were assigned to receive either the statin or the placebo arm (n = 237) at baseline. Patients who were eligible for statin therapy (n = 237) were enrolled and randomized to receive either the statin or the placebo arm (n = 237). All patients received at least one additional statin prescription per day (Table 1). The primary endpoint was a composite measure of the primary composite measure of (3) change from baseline in LDL cholesterol (LDL-C) and (4) change from baseline in HDL cholesterol (HDL-C) (all analyses were performed in the primary endpoint). The results of the secondary endpoint were statistically significant.By
AstraZeneca is in a tight spot. The drug maker is expected to pull out of the market in 2014, after a decade of failing to win a second major drug approval.
The UK-based drug maker has been looking for a new medicine to treat an aging heart condition called heart failure, but the world's largest drug company and its partner Pharmacia are facing a challenge.
The market is particularly sensitive to the challenges the drug faces, with drug makers worried about patient safety and side effects. AstraZeneca has lost patent protection for its cholesterol-lowering drug Crestor, and it is also worried that the drug could lose patent protection in 2014.
In addition to the loss of patent protection, the company has been struggling to attract investors, especially in the wake of its failed acquisition of GlaxoSmithKline for about $5 billion last year.
The world's largest drug maker, including AstraZeneca, is in a bind. The UK-based company is in a tight spot, with Pharmacia and its partner, Novartis, also facing an uncertain future in the drug's future.
Novartis faces a similar challenge, as its diabetes drug, Actos, is in a severe state.
The world's largest drug maker, including AstraZeneca, is in a tight spot, with Pharmacia and its partner, Pharmacia, also facing an uncertain future in the drug's future.
Novartis faces a similar challenge, as its cancer drug, Risperdal, is in a serious state.
But in the wake of the collapse of the cholesterol-lowering drug Crestor and the stock market's collapse, a new drug that can treat patients with heart failure has already been approved by the US Food and Drug Administration.
AstraZeneca is in a tight spot, with Pharmacia and its partner, Pharmacia, facing an uncertain future in the drug's future.
AstraZeneca faces a similar challenge, as its cancer drug, Actos, is in a severe state.
Novartis faces a similar challenge, as its cancer drug, Actos, is in a serious state.
Novartis faces a similar challenge, as its cancer drug, Actos, is in a severe state.
Stade de France Pharmacy